Sanofi clinical trial pipeline
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-20
What changed in the last 30 days
48 trials changed in the last 30 days: 2 stopped, 10 with notable changes, 36 with minor changes only.
- Minor: Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab (PROTECT Extension) Trial completed
- Minor: DUPILAB · Data Collection Study of Participants in France Aged 6 Years Old or More With Atopic Dermatitis Receiving Dupilumab Primary and study completion pushed from May 10, 2028 to Jul 5, 2028
- Minor: COLOR UC · Brivekimig · Ulcerative Colitis Trial sites reduced: 69 → 61 locations
- Notable: Acne mRNA Vaccine in Adolescents 12 to 17 Years of Age With Moderate to Severe Acne Phase changed: Phase 2 → Phase 1/2
- Minor: VITALIZE · Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) · Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Trial sites expanded: 133 → 138 locations
- Minor: PERSEPHONE · Lunsekimig Compared With Placebo · Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype Trial sites expanded: 314 → 322 locations
- Minor: COLOSSUS · Lunsekimig · Chronic Obstructive Pulmonary Disease (COPD) Trial sites expanded: 8 → 16 locations
- Minor: Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry Trial sites expanded: 318 → 324 locations
- Minor: Fabry Disease Registry & Pregnancy Sub-registry Trial sites expanded: 284 → 289 locations
- Notable: Combination SARS-CoV-2 Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M Adjuvant in Adult Participants 60 Years of Age and Older Recruitment opened
- Minor: Different Formulations of Vaccines Encoding the RSV Monovalent Antigen or the Flu H5 Antigen in Participants 18 to 49 Years of Age Enrollment closed, study ongoing
- Minor: Observe & Describe Clinical Outcomes of Alglucosidase Alfa Treatment in Patients ≤6 Months of Age With Infantile-onset Pompe Disease (IOPD) Trial completed
- Minor: SAR444336 · Microscopic Colitis in Clinical Remission Enrollment closed, study ongoing
- Minor: Recombinant Spike COVID-19 Vaccine With Matrix-M in Older Adults and People at Increased Risk of Severe COVID-19 Enrollment closed, study ongoing
- Minor: Agalsidase Beta Long-Term Treatment Outcome for Fabry Disease · IVS4 Mutation in Taiwan Trial completed
- Minor: LUNA 4 · Oral Rilzabrutinib · Immune Thrombocytopenia (ITP) Who Failed First-line Treatment Trial sites expanded: 36 → 54 locations
- Minor: RESULT · Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease Trial sites expanded: 79 → 82 locations
- Minor: Plasma Concentration of Belumosudil Given as an Oral Suspension and as a Tablet to Healthy Adult Male Participants Primary and study completion pushed from Sep 28, 2026 to Jan 26, 2027
- Minor: Rilzabrutinib for the Adult · Chronic ITP Who Have Completed Phase 3 Study in Japan Final enrollment: 3 participants (planned 4)
- Minor: Belumosudil in Participants Aged 12 Years and Above, With Chronic Graft-versus-host Disease (cGVHD) Start date pushed from Oct 30, 2026 to Nov 20, 2026
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
New trial filings, last 30 days
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-11-18 | NCT07944885 First-in-human Study of SAR448632 in Healthy Adult Participants | Phase 1 | Not Yet Recruiting |
| 2026-11-17 | NCT07941622 Study of Hexaxim Compared With Pentaxim Administered With a Monovalent Hepatitis B… | Phase 3 | Not Yet Recruiting |
| 2026-11-12 | NCT07930624 A Study to Investigate Long-term Safety and Tolerability of Frexalimab in Participants… | Phase 3 | Not Yet Recruiting |
| 2026-11-10 | NCT07927140 The Efficacy and Safety of Venglustat Compared With Cerezyme in Pediatric Participants 2… | Phase 3 | Not Yet Recruiting |
| 2026-11-06 | NCT07923305 Phase 2 and 3 Placebo Controlled & Long-term Extension Study of Rilzabrutinib in Adults… | Phase 2/3 | Not Yet Recruiting |
| 2026-11-06 | NCT07923383 An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected… | Phase 1 | Not Yet Recruiting |
| 2026-11-05 | NCT07919899 Pharmacokinetics, Immunogenicity and Safety of Subcutaneous Dupilumab and… | Phase 3 | Not Yet Recruiting |
| 2026-10-30 | NCT07906132 A Retrospective Cohort Study Evaluating Major Adverse Cardiovascular Events and… | Completed | |
| 2026-10-29 | NCT07905508 A Retrospective Cohort Study Evaluating Major Adverse Cardiovascular Events and… | Completed | |
| 2026-10-29 | NCT07905534 A Retrospective Cohort Study Evaluating Major Adverse Cardiovascular Events and… | Active, Not Recruiting |
Active trials by phase
| Phase 1 | 13 | |
| Phase 1/2 | 15 | |
| Phase 2 | 37 | |
| Phase 2/3 | 3 | |
| Phase 3 | 56 | |
| Phase 4 | 13 |
Not charted: 42 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Disease areas by active trials, top 10 of 21
Atopic Dermatitis (16) · Diabetes (10) · Type 1 Diabetes (9) · COPD (8) · Multiple Myeloma (8) · Hemophilia (7) · Multiple Sclerosis (7) · Ulcerative Colitis (6) · Asthma (5) · Crohn's Disease (4)
Get alerts when Sanofi's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.